Safety of SGLT-2 inhibitors in the management of heart failure in the adult congenital heart disease patient population
2024

Safety of SGLT-2 Inhibitors in Heart Failure for Adults with Congenital Heart Disease

Sample size: 18 publication Evidence: low

Author Information

Author(s): Kheiwa Ahmed, Ssembajjwe Brian, Chatta Payush, Nageotte Stephen, Abramov Dmitry

Primary Institution: Loma Linda University

Hypothesis

The study aims to evaluate the safety of SGLT-2 inhibitors in adult congenital heart disease patients with heart failure.

Conclusion

The use of SGLT-2 inhibitors in a small cohort of adult congenital heart disease patients appears safe and well tolerated.

Supporting Evidence

  • 61% of patients had moderate complexity congenital heart disease.
  • Post initiation, there were no significant differences in systolic blood pressure, sodium level, and creatinine level.
  • There was a statistically significant decline in weight after SGLT-2i initiation.

Takeaway

This study looked at 18 adults with heart problems from birth who took a new medicine to help their heart. It found that the medicine was safe for them.

Methodology

A retrospective, single center analysis of 18 patients with adult congenital heart disease and heart failure who were initiated on SGLT-2 inhibitors.

Potential Biases

Practice variability between ACHD centers may limit generalizability.

Limitations

The study is limited by its small sample size and being a single center, non-randomized cohort.

Participant Demographics

The average age of participants was 37 years, with a mix of moderate and great complexity congenital heart disease.

Statistical Information

P-Value

0.0039

Statistical Significance

p=0.0039

Digital Object Identifier (DOI)

10.1016/j.ijcchd.2024.100495

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication